KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Phase 1
30
about 6.3 years
18+
2 sites in NJ
What this study is about
This trial is testing the safety of KK-LC-1 TCR-T cells in people with advanced cancers that express KK-LC-1. Participants will receive a treatment regimen including KK-LC-1 TCR-T cells, aldesleukin, and a conditioning regimen. The goal is to determine the maximum dose of this treatment and assess its effects on the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive KK-LC-1 TCR-T cells
- 2.Take Aldesleukin
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
aldesleukin
Primary: Maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells
Secondary: Adverse events of KK-LC-1 TCR T cells, Tumor response rate
Oncology